

## DAFTAR PUSTAKA

1. Cowie B, Karapanagiotidis T, Enriquez A, Kelly H. Markers of hepatitis B virus infection and immunity in Victoria, Australia, 1995 to 2005. *Aust. N. Z. J. Public Health.* 2010; 34: 72–78.
2. Klarisa C, Liwang F, Hasan I, editors. *Kapita Selekta Kedokteran*. Edisi 4. Jakarta: Media Aesculapius; 2014; jilid 2: p. 683-689. in.
3. Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI. *Riset Kesehatan Dasar 2013*. Jakarta: Kementerian Kesehatan RI 2013.
4. Fadrian F. Terapi Antiviral Pada Sirosis Hati Dekompensata Terkait Infeksi Virus Hepatitis B. *Maj Kedokt Andalas.* 2016;39(1):35.
5. Hall S, Howell J, Visvanathan K. The Yin and the Yang of Treatment for Chronic Hepatitis B — When to Start , When to Stop Nucleos ( t ) ide Analogue Therapy. 2020;1–16.
6. Perhimpunan Peneliti Hati Indonesia (PPHI). *Konsensus Nasional Penatalaksanaan Hepatitis B di Indonesia*. Jakarta: PPHI; 2017.
7. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. *Hepatology.* 2009;49.
8. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B : a 2012 update. *Hepatology international.* 2012.
9. Gani RA. Management of Resistance and Side Effects on Long-Term Antiviral Therapy. In: Gani RA, Hasan I, Sanityoso A, editors. *Recent Development In Hepatopancreatobiliary Diseases. Proceeding of The 8th Liver Update and The 22nd Scientific Meeting of Ina ASL/PPHI 2015*; 2015 Oct 1-4; Jakarta, Indonesia. Jakarta: PPHI; 2015.
10. Members P, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, et al. *CASL / AMMI 2018 GUIDELINES Management of Hepatitis B Virus Infection : 2018 Guidelines from the Canadian Association for the Study of the Liver and Association of Medical Microbiol.*
11. Mustofa S, Kurniawaty E. *Manajemen gangguan saluran serna : Panduan bagi dokter umum*. Bandar Lampung: Aura Printing & Publishing. 2013.
12. Yano Y, Utsumi T, Lusida MI, Hayashi Y. Hepatitis B virus infection in Indonesia. *World J Gastroenterol.* 2015; 21(38): 10714-10720.
13. Sarin SK, Kumar M, Lau GK., Abbas Z, Chan HL, Chen CJ, et al. AsianPacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatology Int.* 2016; 10(1): 98.
14. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age specific HBsAg seroprevalence and endemicity. *Vaccine.* 2012; 30: 2212-9.
15. Price SA, Wilson LM. *Patofisiologi konsep klinis proses-proses penyakit*, edisi ke-6. Jakarta: EGC; 2012. p. 472-500.
16. Perhimpunan Peneliti Hati Indonesia (PPHI). *Konsensus Nasional*

- Penatalaksanaan Hepatitis B di Indonesia. Jakarta: PPHI; 2012.
17. Gunardi H, Zaimi LF, Soedjatmiko, Turyadi, Harahap AR, Muljono DH. Current prevalence of hepatitis B infection among parturient women in Jakarta, Indonesia. *Acta Med Indonesia*. January 2014; 46(1): 3-9.
  18. Soemohardjo S, Gunawan S. Hepatitis B Kronik. In: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editors. *Buku Ajar Ilmu Penyakit Dalam Edisi 5*. Jakarta: Interna Publishing; 2009. p. 2861-70.
  19. Widoyono. *Penyakit Tropis Epidemiologi, Penularan, Pencegahan, dan Pemberantasannya*. Jakarta : Erlangga; 2008.
  20. Knipe DM, Howley P. *Fields Virology*. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013.
  21. Janahi EM. Prevalence and Risk Factors of Hepatitis B Virus Infection in Bahrain, 2000 through 2010. *PLOS ONE*. 2014 February; 9(2).
  22. Thomas HC, Lok AS, Locarnini SA, Zuckerman AJ (eds). *Viral Hepatitis Fourth Edition*. United Kingdom : Wiley Blackwell; 2014.
  23. Institute of Medicine. *Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C*. Washington: National Academies Press; 2010.
  24. Kementerian Kesehatan Republik Indonesia. *Peraturan Menteri Kesehatan No. 53 Tahun 2015 tentang Penanggulangan Hepatitis Virus*; 30 Juli 2015.
  25. WHO. *Guideline for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection*; March 2015: XV.
  26. Arief S. Hepatitis virus. In: Juffrie M, Soenarto SSY, Oswari H, Arief S, Rosalina I, Mulyani NS, editors. *Buku ajar gastroenterologi-hepatologi*. Jakarta: Badan Penerbit IDAI; 2012. p. 294-311.
  27. World Gastroenterology Organisation (WGO). *Global Guideline Hepatitis B Version 2.0*. World Gastroenterology Organisation; 2015.
  28. Hamborsky, Jennifer, Kroger, Andrew, Wolfe, Charles (eds). *Epidemiology and Prevention of Vaccine-Preventable Diseases*. 13th Edition "The Pink Book". Center for Diseases Prevention and Control; 2015:157.
  29. Oakes, Kathryn. *Hepatitis B: prevalence and pathophysiology*. *Nurs Tim* 2014; 110(7):12-13.
  30. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murrad MH. *AASLD Guidelines for Treatment of Chronic Hepatitis B*. *Hepatology*. 2015.
  31. Van Bömmel F, Berg T. *HBV Treatment-Standard of care in Hepatology, a clinical textbook*. Duesseldorf: Flying Publisher. 2009: 119-142.
  32. Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. *Hepatology*. 2011 Nov;
  33. Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or

- seroconversion: a meta-analysis of controlled clinical trials. *BMC Infect Dis*. 2011; 11: 165.
34. Dienstag JL. Hepatitis B virus infection. *New England Journal of Medicine*. 2008 Oct; 359 (14):1486-1500.
  35. Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, et al. Long-term efficacy and safety of Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *Hepatology*. 2008.
  36. European Association for the Study of the Liver (EASL). Clinical Practice Guidelines on the Management of Hepatitis B virus infection, *Journal of Hepatology* 2017; 67: 370-398.
  37. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, et al. A prospective and open-label study for the efficacy and safety of Telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. *J Hepatol* 2011;55:1215–21.
  38. Zhang Y, Hu P, Qi X, Ren H, Mao RC, Zhang JM. A comparison of Telbivudine and Entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China. *Clin Microbiol Infect* 2016.
  39. Brunton LL, Lazo JS, Parker KL. *Goodman & Gilman's the pharmacological basis of therapeutics* 11th ed. California; 2005.
  40. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus Lamivudine for patients with HBeAg-negative chronic hepatitis B. *N Engl J Med*. 2006 Mar 9;354(10):1011-20.
  41. Seo YS, Jung FS, Kim JH. Lamivudine versus Entecavir in patients with hepatitis B virus related decompensated liver cirrhosis. *Journal of Hepatology*. 2010;50: 550A.
  42. Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with Tenofovir disoproxil fumarate for chronic hepatitis B virus infection. *Dig Dis Sci* 2015;60:1457–64.
  43. Liu Y, Corsa AC, Buti M, Cathcart AL, Flaherty JF, Miller MD, et al. No detectable resistance to Tenofovir disoproxil fumarate in HBeAg+ and HBeAg-patients with chronic hepatitis B after 8 years of treatment. *J Viral Hepat* 2017;24:68–74.
  44. Liu F, Wang XW, Chen L, Hu P, Ren H, Hu HD. Systematic review with metaanalysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. *Aliment Pharmacol Ther*. 2016; 43(12):1253-61.
  45. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of Tenofovir disoproxil fumarate treatment for chronic hepatitis B. *Gastroenterology*. 2011 Jan;140(1):132-43.
  46. Hulgán T, Haas DW. Toward a pharmacogenetic understanding of nucleotide and nucleoside analog toxicity. *J Infect Dis* 2006;194:1471-1474.
  47. Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, et al. Management of antiviral resistance in patients with chronic hepatitis B.

Antivir Ther 2004;9:679-693.

48. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of Entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. *Antimicrob Agents Chemother* 2004;48:3498-350.
49. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. *HEPATOLOGY* 2007;46:254-265.
50. Carrouée-Durantel S, Durantel D, Werle-Lapostolle B, Pichoud C, Naesens L, Neyts J, et al. Suboptimal response to Adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naïve patients is not due to pre-existing drug-resistant mutants. *Antiviral*.
51. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus Lamivudine in patients with chronic hepatitis B. *N Engl J Med* 2007 Dec; 357 (25) :2576-2588.
52. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: Telbivudine is superior to Lamivudine in patients with chronic hepatitis B. *Gastroenterology*. 2009 Feb; 136(2):486-95.
53. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of Lamivudine treatment in patients with chronic hepatitis B. *Gastroenterology*. 2003 Dec;125(6):1714-22.
54. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by Lamivudine for chronic hepatitis B. *HEPATOLOGY* 2000;32:1078-1088.
55. Colonna RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. *HEPATOLOGY* 2006;44:1656-1665.
56. Yao GB, Zhu M, Cui AY. A 7-year study of Lamivudine therapy for chronic hepatitis B virus e antigen-positive chronic hepatitis B patients in China. *J Dig Dis* 2009;10:131-137.
57. Yuen M, Fung J, Seto W, Wong D, Chi J, Lai C. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with Lamivudine therapy. *Antivir Therpy* 2009;14:679-85.
58. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang T, Kitis G, Rizzetto M, et al. Long-term therapy with Adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. *Gastroenterology* 2006;131:1743-1751.
59. Locarnini S. Primary resistance, multidrug resistance and cross resistance pathways in HBV as a consequence of treatment failure. *Hepatol Int* 2008.
60. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to Entecavir in nucleoside-naïve patients is rare through 5 years of therapy. *Hepatology*

2009;49:1503–1514.

61. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. *Gastroenterology* 2008;134:405-415.
62. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *Journal of hepatology*. 2012;57(1):167-85.
63. Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, Licari T, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. *Hepatology*. 2011 Jun;53(6):1854-63.
64. Guo X, Wu J, Wei F, Ouyang Y, Li Q, Liu K, et al. Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study. *Int J Antimicrob Agents*. 2018 Aug;52(2):201-209.
65. Lei J, Wang Y, Wang LL, Zhang SJ, Chen W, Bai ZG, Xu LY. Profile of hepatitis B virus resistance mutations against nucleoside/nucleotide analogue treatment in Chinese patients with chronic hepatitis B. *Virology*. 2013 Oct 25;53(3):313-318.
66. Salpini R, Alteri C, Cento V, Pollicita M, Micheli V, Gubertini G, et al. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. *J Med Virol*. 2013 Jun;85(6):996-1004.
67. Xu Y, Zhou H, Chen W, Chen Y, Zhan H, Gong G. Clinical Characteristics, Rescue Treatments, Health Resources Utilization, and Medical Costs Associated with Chinese Chronic Hepatitis B Patients with Drug Resistance to Nucleos(t)ide Analogues: A Retrospective Cohort Study. *Value in Health*. 2018; 21: S85-S91.
68. Shen H, Ding F, Wang Z, Sun F, Yu Y, Zhou J, et al. Comparison of Telbivudine and Entecavir Therapy on Nephritic Function and Drug Resistance in Patients with Hepatitis B Virus-Related Compensated Cirrhosis. *Cell Physiol Biochem*. 2016;40(1-2):370-378.
69. Mokaya J, Maponga TG, McNaughton AL, VanSchalkwyk M, Hugo S, Singer JB, et al. Evidence of Tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults. *Journal of Clinical Virology*. 2020 Aug; 129:1045-48
70. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schwalder J, et al. No resistance to Tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. *Hepatology*. 2011 Mar;53(3):763-73.
71. Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with Tenofovir disoproxil fumarate for chronic hepatitis B virus infection. *Dig Dis Sci*. 2015 May;60(5):1457-64.